Healthcare providers typically monitor your response to IV therapy, evaluating factors such as hydration levels, electrolyte balance, and overall well-being
With semaglutide, its about 16%
In the head-to-head comparison between tirzepatide and semaglutide, the two drugs yielded similar risks for component endpoints all-cause mortality (HR 1.03, 95% CI 0.84 to 1.27), myocardial infarction (HR 1.03, 95% CI 0.88 to 1.21) and stroke (HR 1.15, 95% CI 0.92 to 1.45) (Fig
Leave a comment or question below, or talk to your healthcare provider if youre unsure about your next step
If patients experience severe gastrointestinal symptoms or dehydration, stopping GLP-1 therapy temporarily is advisable